Journal Information

Statistics

Follow this link to access the full text of the article

Case Letter
Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis
Camilla Chello, Alvise Sernicola, Giovanni Paolino, Teresa Grieco
Corresponding author
teresa.grieco@uniroma1.it

Corresponding author.
Dermatology Unit, Sapienza University of Rome, Rome, Italy
Read
4290
Times
was read the article
2003
Total PDF
2287
Total HTML
Share statistics
Article information
ISSN: 03650596
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 May 4 6 10
2024 April 100 91 191
2024 March 101 83 184
2024 February 84 76 160
2024 January 86 50 136
2023 December 54 59 113
2023 November 62 84 146
2023 October 60 64 124
2023 September 72 76 148
2023 August 51 38 89
2023 July 58 46 104
2023 June 50 45 95
2023 May 46 25 71
2023 April 44 23 67
2023 March 41 64 105
2023 February 71 36 107
2023 January 66 38 104
2022 December 62 37 99
2022 November 86 62 148
2022 October 100 59 159
2022 September 82 78 160
2022 August 50 44 94
2022 July 61 71 132
2022 June 53 50 103
2022 May 38 40 78
2022 April 62 63 125
2022 March 68 67 135
2022 February 38 42 80
2022 January 70 82 152
2021 December 69 75 144
2021 November 85 63 148
2021 October 121 110 231
2021 September 121 82 203
2021 August 44 54 98
2021 July 27 20 47
Show all

Follow this link to access the full text of the article

Idiomas
Anais Brasileiros de Dermatologia
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.